Who is sponsoring NCT03508245?

NCT03508245 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT03508245?

Interventions in NCT03508245: Wearable short wavelength light therapy.

What condition does NCT03508245 study?

NCT03508245 studies Tourette's Disorder.

Is NCT03508245 still recruiting?

NCT03508245 is currently completed. Last updated 12 December 2023.

Last reviewed 2023-12-12 · How we verify

NCT03508245

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigating Circadian Rhythms in Youth With Persistent Tic Disorders

Completed NA Last updated 12 December 2023

What this trial tests

NA trial testing Wearable short wavelength light therapy in Tourette's Disorder in 35 participants. Completed in 23 June 2023.

Timeline

18 January 2018

Primary endpoint
23 June 2023

23 June 2023

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	18 January 2018
Primary completion	23 June 2023
Estimated completion	23 June 2023
Sites	1 location across United States

Drugs / interventions tested

Wearable short wavelength light therapy

Conditions studied

Tourette's Disorder — all drugs for Tourette's Disorder →

Sponsor

University of California, Los Angeles

Who can join

Adults 13 to 17, any sex, with Tourette's Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study examines circadian rhythms and morningness-eveningness preference in youth with Persistent Tic Disorders (PTDs), including Tourette's Disorder (TD); and assesses the effects of wearable short wavelength light therapy on circadian rhythms and tic symptoms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03508245 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 12 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03508245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing